Annual Accounts Receivable
N/A
September 30, 2024
Summary
- ARWR annual accounts receivable is not available.
Performance
ARWR Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
N/A
September 30, 2024
Summary
- ARWR quarterly accounts receivable is not available.
Performance
ARWR Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
ARWR Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | - |
| 3 y3 years | - | - |
| 5 y5 years | - | - |
ARWR Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | ||||
| 5 y | 5-year | ||||
| alltime | all time |
Arrowhead Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $1.25 M(-98.2%) |
| Mar 2023 | - | $69.43 M(+75.5%) |
| Dec 2022 | - | $39.57 M(+2706.2%) |
| Sep 2022 | $1.41 M(-86.3%) | $1.41 M(+490.0%) |
| Jun 2022 | - | $239.00 K(-81.9%) |
| Mar 2022 | - | $1.32 M(+778.0%) |
| Dec 2021 | - | $150.00 K(-98.5%) |
| Sep 2021 | $10.26 M(+1112.2%) | $10.26 M(+1428.3%) |
| Jun 2021 | - | $671.00 K(-29.7%) |
| Mar 2021 | - | $955.00 K(-89.4%) |
| Dec 2020 | - | $9.00 M(+964.1%) |
| Sep 2020 | $846.00 K(+27.9%) | $846.00 K(-96.1%) |
| Jun 2020 | - | $21.69 M(+1613.7%) |
| Mar 2020 | - | $1.27 M(-5.9%) |
| Dec 2019 | - | $1.35 M(+103.4%) |
| Sep 2019 | $661.40 K(+102.0%) | $661.40 K(-67.6%) |
| Jun 2019 | - | $2.04 M(-84.8%) |
| Mar 2019 | - | $13.42 M(+323.6%) |
| Dec 2018 | - | $3.17 M(+867.8%) |
| Sep 2018 | $327.40 K(+382.9%) | $327.40 K(+2082.7%) |
| Jun 2018 | - | $15.00 K(-8.0%) |
| Mar 2018 | - | $16.30 K(-89.1%) |
| Dec 2017 | - | $149.90 K(+121.1%) |
| Sep 2017 | $67.80 K(-9.6%) | $67.80 K(-92.8%) |
| Jun 2017 | - | $937.30 K(+61.4%) |
| Mar 2017 | - | $580.80 K(+868.0%) |
| Dec 2016 | - | $60.00 K(-20.0%) |
| Sep 2016 | $75.00 K(>+9900.0%) | $75.00 K(>+9900.0%) |
| Sep 2015 | $0.00(-100.0%) | $0.00(-100.0%) |
| Dec 2014 | - | $127.00 K(>+9900.0%) |
| Jun 2014 | - | $0.00(0.0%) |
| Mar 2014 | - | $0.00(-100.0%) |
| Dec 2013 | - | $75.00 K(0.0%) |
| Sep 2013 | $75.00 K(+697.9%) | $75.00 K(>+9900.0%) |
| Jun 2013 | - | $0.00(0.0%) |
| Mar 2013 | - | $0.00(-100.0%) |
| Dec 2012 | - | $115.30 K(+1126.6%) |
| Sep 2012 | $9400.00 | $9400.00(-98.6%) |
| Jun 2012 | - | $677.40 K(+2884.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $22.70 K(-98.6%) |
| Sep 2011 | $1.61 M(+2630.7%) | $1.61 M(+19.1%) |
| Jun 2011 | - | $1.35 M(+6.5%) |
| Mar 2011 | - | $1.27 M(-72.4%) |
| Dec 2010 | - | $4.59 M(+7688.1%) |
| Sep 2010 | $58.90 K(-59.1%) | $58.90 K(+520.0%) |
| Jun 2010 | - | $9500.00(-83.0%) |
| Mar 2010 | - | $55.90 K(-56.9%) |
| Dec 2009 | - | $129.80 K(-9.9%) |
| Sep 2009 | $144.10 K(+3414.6%) | $144.10 K(-63.4%) |
| Jun 2009 | - | $393.80 K(+243.3%) |
| Mar 2009 | - | $114.70 K(-1.5%) |
| Dec 2008 | - | $116.40 K(+2739.0%) |
| Sep 2008 | $4100.00(-98.5%) | $4100.00(-95.7%) |
| Jun 2008 | - | $94.40 K(+12.5%) |
| Mar 2008 | - | $83.90 K(-79.1%) |
| Dec 2007 | - | $401.00 K(+46.4%) |
| Sep 2007 | $273.90 K(+965.8%) | $273.90 K(+72.6%) |
| Jun 2007 | - | $158.70 K(+4189.2%) |
| Dec 2006 | - | $3700.00(-89.2%) |
| Jun 2006 | - | $34.40 K(-14.0%) |
| Mar 2006 | - | $40.00 K(+33.3%) |
| Dec 2005 | - | $30.00 K(+16.7%) |
| Sep 2005 | $25.70 K(-50.4%) | $25.70 K(-70.4%) |
| Jun 2005 | - | $86.70 K(+3234.6%) |
| Dec 2004 | - | $2600.00(-95.0%) |
| Sep 2004 | $51.80 K(+8533.3%) | $51.80 K(>+9900.0%) |
| Jun 2002 | - | $100.00(0.0%) |
| Mar 2002 | - | $100.00(-92.9%) |
| Dec 2001 | - | $1400.00(+133.3%) |
| Sep 2001 | $600.00(-53.8%) | $600.00(-72.7%) |
| Dec 2000 | - | $2200.00(+69.2%) |
| Sep 2000 | $1300.00(-88.5%) | $1300.00(-18.8%) |
| Jun 2000 | - | $1600.00(+6.7%) |
| Mar 2000 | - | $1500.00(+36.4%) |
| Dec 1999 | - | $1100.00 |
| Sep 1999 | $11.30 K(+253.1%) | - |
| Sep 1998 | $3200.00(-69.2%) | - |
| Sep 1997 | $10.40 K | - |
FAQ
- What is the all time high annual accounts receivable for Arrowhead Pharmaceuticals?
- What is the all time high quarterly accounts receivable for Arrowhead Pharmaceuticals?
What is the all time high annual accounts receivable for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual accounts receivable is $10.26 M
What is the all time high quarterly accounts receivable for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly accounts receivable is $69.43 M